Coverage
The Organon Access Program for ONTRUZANT can help answer questions about:
If your patient is eligible and interested in co-pay assistance or the Organon Patient Assistance Program, please complete the appropriate sections on the form.
ONTRUZANT is indicated in adults for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
ONTRUZANT is indicated in adults:
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
ONTRUZANT is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
ER = estrogen receptor
HER2 = human epidermal growth factor receptor 2
PR = progesterone receptor
MUGA = multigated acquisition
NCI-CTC = National Cancer Institute-Common Terminology Criteria
PK = pharmacokinetics
Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.